EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study

Pablo García-Pavía, José Manuel García-Pinilla, Ainara Lozano-Bahamonde, Sergi Yun, Antonio García-Quintana, Juan José Gavira-Gómez, Miguel Ángel Aibar-Arregui, Gonzalo Barge-Caballero, Julio Núñez Villota, Laura Bernal, Patricia Tarilonte

Revista Española de Cardiología (English Edition) · 2025-04 · 78 (4) · 301-310

DOI: 10.1016/j.rec.2024.07.005 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Revista Española de Cardiología (English Edition), 2025-04. Verfasst von Pablo García-Pavía und 10 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Cardiología, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana …. Hauptthemen laut MEDLINE: Stroke Volume, Heart Failure, Amyloid Neuropathies, Familial, Ventricular Function, Left. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION AND OBJECTIVES: Transthyretin cardiac amyloidosis (ATTR-CA) is a frequent cause of heart failure with preserved ejection fraction (HFpEF). This study sought to determine the prevalence of ATTR-CA among HFpEF patients in a multicenter nationwide study. METHODS: Consecutive ambulatory or hospitalized patients aged ≥ 50 years with HFpEF and left ventricle hypertrophy ≥ 12mm were studied at 20 Spanish hospitals. Screening for cardiac amyloidosis was initiated according to the usual clinical practice of each center. Positive scintigraphs were centrally analyzed. RESULTS: 422 patients were included, of whom 387 underwent further screening for cardiac amyloidosis. A total of 65 patients (16.8%) were diagnosed with ATTR-CA, none below 75 years. There was an increase of prevalence with age. Of them, 60% were male, with a mean age of 85.3±5.2 years, mean left ventricle ejection fraction of 60.3±7.6% and a mean maximum left ventricle wall thickness of 17.2 [12-25] mm. Most of the patients were New York Heart Association class II (48.4%) or III (46.8%). Besides being older than non-ATTR-CA patients, ATTR-CA patients had higher median NT-proBNP levels (3801 [2266-7132] vs 2391 [1141-4796] pg/mL; P=.003). There was no statistical difference in the prevalence of ATTR-CA by sex (19.7% for men and 13.8% for women, P=.085). A ∼7% (4/56) of the patients exhibited a genetic variant (ATTRv). CONCLUSIONS: This multicenter nationwide study found a prevalence of 16.8%, confirming that ATTR-CA is a significant contributor to HFpEF in male and female patients with left ventricle hypertrophy and more than 75 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stroke VolumeHeart FailureAmyloid Neuropathies, FamilialVentricular Function, LeftCardiomyopathiesHumansMaleFemalePrevalenceAgedAged, 80 and overMiddle AgedSpainPrealbumin

Stichwörter der Autor:innen

Amiloidosis cardiacaAmiloidosis cardiaca por transtirretinaCardiac amyloidosisFracción de eyección conservadaHeart failureHipertrofia del ventrículo izquierdoInsuficiencia cardiacaLeft ventricular hypertrophyPreserved ejection fractionPrevalencePrevalenciaTransthyretinTransthyretin cardiac amyloidosisTranstirretina

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Servicio de Cardiología, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Madrid, Spain; Centro de Investigación Biomédica en Red de…
  • Servicio de Cardiología, Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Universidad de Málaga, Málaga, Spain.
  • Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital Universitario Basurto, Bilbao, Vizcaya, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain; Bio-Heart, Grupo de Investigación en Enfermedades Cardiovasculares, Instituto de Investigación Biomédica de Bellvitge (IDIBELL)…
  • Servicio de Cardiología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain.
  • Servicio de Cardiología, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.

Förderung

  • Pfizer UK

Zitieren

APA

García-Pavía, P., García-Pinilla, J. M., Lozano-Bahamonde, A., Yun, S., García-Quintana, A., Gavira-Gómez, J. J., Aibar-Arregui, M. Á., Barge-Caballero, G., Núñez Villota, J., Bernal, L., & Tarilonte, P. (2025). Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study. Revista Española de Cardiología (English Edition), 78(4), 301-310. https://doi.org/10.1016/j.rec.2024.07.005

Vancouver

García-Pavía P, García-Pinilla JM, Lozano-Bahamonde A, Yun S, García-Quintana A, Gavira-Gómez JJ, et al. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study. Revista Española de Cardiología (English Edition). 2025;78(4):301-310. doi:10.1016/j.rec.2024.07.005

BibTeX
@article{GarcaPava2025,
  author = {García-Pavía, Pablo and García-Pinilla, José Manuel and Lozano-Bahamonde, Ainara and Yun, Sergi and García-Quintana, Antonio and Gavira-Gómez, Juan José and Aibar-Arregui, Miguel Ángel and Barge-Caballero, Gonzalo and Núñez Villota, Julio and Bernal, Laura and Tarilonte, Patricia},
  title = {Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study},
  journal = {Revista Española de Cardiología (English Edition)},
  year = {2025},
  volume = {78},
  number = {4},
  pages = {301--310},
  doi = {10.1016/j.rec.2024.07.005}
}
Kostenlos starten →